Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
On Thursday, Halozyme Therapeutics, Inc. (NASDAQ: HALO) submitted a non-binding proposal to Evotec SE (NASDAQ: EVO) to acquire the German company for 11.00 euros per share in cash, implying a fully ...